RedHill Biopharma Ltd. (RDHL)
USD 2.37
(8.99%)
USD 2.37
(8.99%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 26.26 Million USD | 15.14% |
| 2022 | -42.84 Million USD | 45.07% |
| 2021 | -63.02 Million USD | -15.24% |
| 2020 | -54.93 Million USD | -34.48% |
| 2019 | -40.78 Million USD | -5.42% |
| 2018 | -38.6 Million USD | 15.03% |
| 2017 | -45.78 Million USD | -56.77% |
| 2016 | -30.49 Million USD | -38.91% |
| 2015 | -21.86 Million USD | -102.33% |
| 2014 | -10.62 Million USD | 2.73% |
| 2013 | -10.74 Million USD | -16.45% |
| 2012 | -9.01 Million USD | -8.46% |
| 2011 | -7.85 Million USD | -366.87% |
| 2010 | -2.54 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | 2.68 Million USD | -97.58% |
| 2023 Q1 | 111.14 Million USD | 37905.1% |
| 2023 FY | - USD | 15.14% |
| 2022 Q3 | -1.82 Million USD | 67.28% |
| 2022 Q1 | -11.09 Million USD | -15.68% |
| 2022 Q2 | -5.58 Million USD | 49.68% |
| 2022 FY | - USD | 45.07% |
| 2022 Q4 | -294 Thousand USD | 83.9% |
| 2021 Q2 | -22.57 Million USD | -42.97% |
| 2021 Q3 | -15.04 Million USD | 33.38% |
| 2021 Q4 | -9.58 Million USD | 36.26% |
| 2021 FY | - USD | -15.24% |
| 2021 Q1 | -15.79 Million USD | 9.95% |
| 2020 FY | - USD | -34.48% |
| 2020 Q1 | -16.19 Million USD | -46.1% |
| 2020 Q2 | -10.2 Million USD | 36.99% |
| 2020 Q3 | -11.83 Million USD | -16.05% |
| 2020 Q4 | -17.53 Million USD | -48.12% |
| 2019 Q3 | -9.38 Million USD | 11.52% |
| 2019 Q1 | -8.6 Million USD | 17.1% |
| 2019 Q2 | -10.6 Million USD | -23.23% |
| 2019 FY | - USD | -5.42% |
| 2019 Q4 | -11.08 Million USD | -18.08% |
| 2018 FY | - USD | 15.03% |
| 2018 Q4 | -10.38 Million USD | -8.38% |
| 2018 Q3 | -9.58 Million USD | -2.16% |
| 2018 Q2 | -9.37 Million USD | 4.69% |
| 2018 Q1 | -9.83 Million USD | 5.18% |
| 2017 Q3 | -13.78 Million USD | -25.38% |
| 2017 Q4 | -10.37 Million USD | 24.74% |
| 2017 FY | - USD | -56.77% |
| 2017 Q2 | -10.99 Million USD | -28.9% |
| 2017 Q1 | -8.53 Million USD | -7.09% |
| 2016 FY | - USD | -38.91% |
| 2016 Q4 | -7.96 Million USD | 4.4% |
| 2016 Q3 | -8.33 Million USD | -27.88% |
| 2016 Q2 | -6.51 Million USD | -18.21% |
| 2016 Q1 | -5.51 Million USD | 15.57% |
| 2015 Q1 | -4.46 Million USD | 7.2% |
| 2015 FY | - USD | -102.33% |
| 2015 Q4 | -6.53 Million USD | -106.45% |
| 2015 Q3 | -3.16 Million USD | 44.65% |
| 2015 Q2 | -5.71 Million USD | -28.14% |
| 2014 FY | - USD | 2.73% |
| 2014 Q4 | -4.8 Million USD | -24.54% |
| 2014 Q2 | -3.97 Million USD | -215.62% |
| 2014 Q1 | 3.43 Million USD | 200.26% |
| 2014 Q3 | -3.85 Million USD | 2.92% |
| 2013 FY | - USD | -16.45% |
| 2013 Q2 | -2.5 Million USD | -27.24% |
| 2013 Q1 | -1.96 Million USD | 6.55% |
| 2013 Q3 | -2.68 Million USD | -7.39% |
| 2013 Q4 | -3.42 Million USD | -27.52% |
| 2012 Q4 | -2.1 Million USD | -9.57% |
| 2012 Q1 | -2.66 Million USD | -8.76% |
| 2012 Q3 | -1.92 Million USD | 4.95% |
| 2012 Q2 | -2.02 Million USD | 24.21% |
| 2012 FY | - USD | -8.46% |
| 2011 FY | - USD | -366.87% |
| 2011 Q3 | -2.21 Million USD | 0.0% |
| 2011 Q4 | -2.45 Million USD | -10.69% |
| 2010 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alvotech | -484.86 Million USD | 105.417% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 91.481% |
| Journey Medical Corporation | 1.92 Million USD | -1267.316% |
| Dynavax Technologies Corporation | 9.66 Million USD | -171.737% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 116.535% |
| PainReform Ltd. | -9.56 Million USD | 374.492% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 786.801% |
| SCYNEXIS, Inc. | 73.47 Million USD | 64.254% |
| Silver Spike Investment Corp. | 7.34 Million USD | -257.844% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 786.801% |
| Bright Green Corporation | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 117.498% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -2122.178% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 75.973% |
| Alpha Teknova, Inc. | -25.53 Million USD | 202.847% |
| Embecta Corp. | 245.4 Million USD | 89.297% |
| Safety Shot Inc | -12.18 Million USD | 315.558% |
| Procaps Group, S.A. | 104.02 Million USD | 74.751% |
| Cosmos Health Inc. | -17.06 Million USD | 253.947% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 1217.228% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 83.876% |
| Theratechnologies Inc. | -10.31 Million USD | 354.695% |
| Harrow Health, Inc. | 9.72 Million USD | -170.144% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 680.467% |
| Biofrontera Inc. | -18.45 Million USD | 242.341% |
| DURECT Corporation | -24.68 Million USD | 206.41% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 73.269% |
| Cronos Group Inc. | -72.14 Million USD | 136.405% |
| OptiNose, Inc. | -15.55 Million USD | 268.882% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 102.84% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 172.796% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 27.101% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 769.652% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 3795.033% |
| Radius Health, Inc. | 38.31 Million USD | 31.438% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 916.97% |
| ProPhase Labs, Inc. | -14.82 Million USD | 277.151% |
| Phibro Animal Health Corporation | 84.6 Million USD | 68.955% |
| Procaps Group S.A. | 104.02 Million USD | 74.751% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 412.655% |
| Viatris Inc. | 3.51 Billion USD | 99.253% |
| Rockwell Medical, Inc. | -4.69 Million USD | 659.568% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 2695.468% |
| SIGA Technologies, Inc. | 84.15 Million USD | 68.79% |
| Tilray Brands, Inc. | -72.84 Million USD | 136.059% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -3134.746% |
| Shineco, Inc. | -26.55 Million USD | 198.916% |
| PetIQ, Inc. | 81.48 Million USD | 67.766% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 826.06% |
| Incannex Healthcare Limited | -18.5 Million USD | 241.948% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 93.688% |
| Alimera Sciences, Inc. | 7.27 Million USD | -260.997% |
| Assertio Holdings, Inc. | -222.44 Million USD | 111.808% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 758.192% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 723.622% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 256.309% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 231.129% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 117.614% |
| Hempacco Co., Inc. | -12.77 Million USD | 305.634% |
| Talphera, Inc. | -9.84 Million USD | 366.878% |
| Alvotech | -484.86 Million USD | 105.417% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 66.109% |
| Lantheus Holdings, Inc. | 491 Million USD | 94.651% |
| Currenc Group, Inc. | -1.9 Million USD | 1482.011% |
| Kamada Ltd. | 21.53 Million USD | -21.975% |
| Indivior PLC | 66 Million USD | 60.203% |
| Evoke Pharma, Inc. | -7.29 Million USD | 460.19% |
| Flora Growth Corp. | -45.87 Million USD | 157.262% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 231.129% |
| Evolus, Inc. | -41.81 Million USD | 162.823% |
| HUTCHMED (China) Limited | 25.52 Million USD | -2.891% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 89.122% |
| Akanda Corp. | -27.73 Million USD | 194.702% |